Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Catequentinib - Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical

Drug Profile

Catequentinib - Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical

Alternative Names: AL-3818; ALTN; Anlotinib; Anlotinib hydrochloride; Anrotinib; FOCUS V

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories; Jiangsu Chia-Tai Tianqing Pharmaceutical
  • Developer Advenchen Laboratories; Akeso Biopharma; Chia Tai Tianqing Pharmaceutical Group; Henan Cancer Hospital; Peking University People's Hospital; Tianquan Pharmaceutical
  • Class Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorinated hydrocarbons; Indoles; Quinolines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Alveolar soft part sarcoma; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Liver cancer; Nasopharyngeal cancer; Soft tissue sarcoma; Synovial sarcoma; Thyroid cancer
  • Phase II Bone cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Ewing's sarcoma; Fallopian tube cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Phase I/II Acral lentiginous melanoma; Endometrial cancer
  • No development reported Solid tumours

Most Recent Events

  • 18 Jan 2024 Efficacy and adverse events data from the phase II ALTER-G-001 trial in Gastrointestinal cancer presented at Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 20 Oct 2023 Efficacy and safety data from the phase II trial in cervical cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 20 Oct 2023 Updated efficacy and safety data from the phase II neoALTALL trial in Triple-negative-breast-cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top